Q2 EPS Estimate for Gain Therapeutics Reduced by Analyst
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Equities researchers at Roth Capital reduced their Q2 2025 earnings per share estimates for Gain Therapeutics in a note issued to investors on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($0.18) per share for the quarter, down from their […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) – Equities researchers at Roth Capital reduced their Q2 2025 earnings per share estimates for Gain Therapeutics in a note issued to investors on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now anticipates that the company will earn ($0.18) per share for the quarter, down from their […]
